IGKV2-26

Across TCGA pan-cancer cohorts, IGKV2-26 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of IGKV2-26’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where IGKV2-26 RNA is repressed in tumor relative to normal tissue. In most cancer types IGKV2-26 is over-expressed in tumor, although a few such as BRCA and COAD show the opposite, repressed pattern.

BRCA, COAD, and LUAD are the cancer types where IGKV2-26 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGKV2-26 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	II,III,IV	−0.254	.035	6	view →
COAD	Female	III,IV	−1.632	<.001	5	view →
LUAD	Female	All	+1.103	<.001	5	view →
READ	All	All	−1.033	.002	3	view →
KIRC	Male	All	+0.261	<.001	3	view →
STAD	All	IV	−4.186	.004	2	view →
THCA	Male	III,IV	+0.261	.045	1	view →
KIRP	All	All	−0.166	.042	1	view →
LIHC	Male	All	−0.142	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

IGKV2-26–BRCA

Open the BRCA breakdown →